13 Feb 2026

Invitation to presentation of Xbrane Biopharma’s Year-end report 2025 on February 20, 2026

24 Nov 2025

Xbrane Biopharma resolves to issue 420,517 warrants to Fenja Capital II A/S under the conditional financing solution

19 Nov 2025

XBRANE UPDATES ON TIMING FOR RESUBMISSION OF THE BLA FOR ITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA

04 Nov 2025

First patient included in Xdivane pivotal clinical trial

03 Nov 2025

THE NUMBER OF SHARES AND VOTES IN XBRANE HAS CHANGED AS A RESULT OF THE PREVIOUSLY ANNOUNCED REVERSE SPLIT OF 1:125.

28 Oct 2025

Xbrane publishes answers to questions received in recent days.

28 Oct 2025

Siavash Bashiri sells shares to repay loan taken in connection with the 2024 rights issue, but remains a dedicated and long-term employee and shareholder

24 Oct 2025

Xbrane Biopharma releases Interim Report for January-September 2025

20 Oct 2025

XBRANE BIOPHARMA PRESENTS THE NOMINATION COMMITTEE

20 Oct 2025

Invitation to presentation of Xbrane Biopharma’s interim report January – September 2025 on October 24, 2025

19 Oct 2025

Xbrane provides Regulatory update on FDA review of its ranibizumab biosimilar candidate

16 Oct 2025

Xbrane Biopharma enters into conditional financing solution with Fenja Capital II A/S

15 Oct 2025

Record date for reverse share split in Xbrane Biopharma AB

13 Oct 2025

Announcement from extra general meeting in Xbrane Biopharma AB

30 Sep 2025

XBRANE BIOPHARMA AB (“XBRANE” OR THE “COMPANY”) HAS ACCORDING TO PREVIOUSLY ANNOUNCED INFORMATION RESOLVED TO CARRY OUT A DIRECTED ISSUE OF IN TOTAL 25,990,000 SHARES